Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal
MarketWatch
with $SRPT gap to 125 this morning that is the 5th time in three months it has had a price gap of greater than 10%.
honestly, this is the dumbest real company i've seen in the past twenty years. https://t.co/6fLeRX9qqH
@sspencer_smb
4 Stock Market Morning Movers: $MSTR $MNDY $SRPT $INTU
Check out the Details 👇 https://t.co/jPHkZ88TBo